ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts

6 days ago · Investment analysts at BTIG Research started coverage on shares of ImmunityBio (NASDAQ:IBRX - Get Free Report) in a research report issued to clients and investors on …

$6.00
OFF

BTIG Initiates ImmunityBio Stock With Buy Rating, Cites Potential Of ...

2 weeks from now

6 days ago · On Friday, BTIG initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) with a Buy rating and a price target of $6.00. The firm sees potential in the company's lead product, …

investing.com

$6
OFF

ImmunityBio Initiated With A Buy At BTIG | Markets Insider

2 weeks from now

6 days ago · BTIG analyst Justin Zelin initiated coverage of ImmunityBio with a Buy rating and $6 price target Lead product Anktiva is approved in BCG-unresponsive non-muscle invasive …

businessinsider.com

6%
OFF

ImmunityBio (NASDAQ:IBRX) Stock Price Up 2.6% - What's Next?

2 weeks from now

Dec 27, 2024 · Analyst Ratings Changes. A number of research analysts have issued reports on the stock. D. Boral Capital reissued a "buy" rating and set a $30.00 target price on shares of …

marketbeat.com

$8
OFF

ImmunityBio, Inc.: Target Price Consensus And Analysts …

2 weeks from now

Dec 2, 2024 · ImmunityBio, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: IBRX | Nasdaq. ... Jefferies Starts ImmunityBio at Buy With $8 Price Target 22-08-03: …

marketscreener.com

58%
OFF

ImmunityBio, Inc. (IBRX) Stock Price, Quote & News - Stock Analysis

2 weeks from now

3 days ago · Analysts: Strong Buy: Price Target: 13.58 (+447.58%) Earnings Date: ... According to 3 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price …

stockanalysis.com

4%
OFF

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.

2 weeks from now

Nov 19, 2024 · The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after …

nasdaq.com

19%
OFF

Why ImmunityBio, Inc. (IBRX) Is The Top Small Cap Stock To Buy …

2 weeks from now

3 days ago · ImmunityBio, Inc. (NASDAQ:IBRX) Analyst Upside: 200.19%. Market Cap: $1.94 billion ... Overall, IBRX ranks first on our list of top 10 small cap stocks to buy with the highest …

investingchannel.com

50%
OFF

D. Boral Capital Reiterates "Buy" Rating For ImmunityBio …

2 weeks from now

Jan 6, 2025 · ImmunityBio Price Performance. Analysts see over 50% gains in these 2 mid-cap biotech stocks; NASDAQ IBRX traded up $0.05 on Monday, hitting $2.86. 950,537 shares of …

marketbeat.com

FAQs about ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts Coupon?

Should you buy immunitybio (IBRX – get free report)?

ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock. Separately, EF Hutton Acquisition Co. ...

How much does immunitybio stock cost?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for ImmunityBio is $17.38, with a high forecast of $30.00 and a low forecast of $4.75. Should I buy or sell ImmunityBio stock right now? ...

How much does immunitybio (IBRX) earn per share?

ImmunityBio (NASDAQ:IBRX) has a recorded net income of -$583.20 million. IBRX has generated -$1.09 earnings per share over the last four quarters. What is ImmunityBio's EPS forecast for next year? ImmunityBio's earnings are expected to grow from ($0.75) per share to ($0.52) per share in the next year. ...

Why is immunitybio (IBRX) stock a parabolic stock?

ImmunityBio (NASDAQ: IBRX) stock price has risen rapidly for two straight days and is now sitting at its highest level... The recent approval of Anktiva, its cancer drug, has sparked investor enthusiasm. ...

Does immunitybio (IBRX) have a Marketing Authorization Application?

ImmunityBio, Inc. (NASDAQ:IBRX) plans to expand its product globally and submitted a Marketing Authorization Application (MAA) for ANKTIVA in 30 countries in the EU in fiscal Q4 2024. It also submitted ANKTIVA for potential approval to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. ...